GANX Gain Therapeutics, Inc.

Gain Therapeutics is redefining drug discovery with its See-Tx target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding.

$3.92  +0.04 (1.03%)
As of 06/24/2022 16:00:01 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/18/2021
Outstanding shares:  11,883,368
Average volume:  77,530
Market cap:   $46,107,468
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -3.35
PB ratio:   1.46
PS ratio:   331.24
Return on equity:   -39.90%
Net income %:   -9,979.03%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy